Azithromycin ophthalmic - InSite Vision

Drug Profile

Azithromycin ophthalmic - InSite Vision

Alternative Names: AzaSite; Azasite; AzaSite Xtra; azithromycin ophthalmic 1%; azithromycin ophthalmic 2%; ISV-401; ISV-405

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InSite Vision
  • Developer Akorn; InSite Vision; Merck & Co
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Conjunctivitis

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Ophthalmic infections
  • Discontinued Blepharitis; Infectious keratitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ophthalmic-infections in USA (Ophthalmic, Drops)
  • 10 Aug 2016 Nicox trasfers the rights for Azithromycin opthalmic in Europe, Africa and Middle East to a pan-European ophthalmic specialty pharmaceutical company
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top